TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05462106: A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Sponsor: AC Immune SA · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 304 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,539,460

Rescue Site Savings

+$1,681,980

Unlock Full NCT05462106 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05462106 Rescue Dossier →